125 related articles for article (PubMed ID: 37561357)
1. Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib.
Lawson McLean A
J Neurooncol; 2023 Aug; 164(1):267-268. PubMed ID: 37561357
[No Abstract] [Full Text] [Related]
2. Targeted anticonvulsive treatment of IDH-wildtype glioblastoma based on DNA methylation subclasses.
Drexler R; Göttsche J; Sauvigny T; Schüller U; Khatri R; Hausmann F; Hänzelmann S; Huber TB; Bonn S; Heiland DH; Delev D; Venkataramani V; Winkler F; Weller J; Zeyen T; Herrlinger U; Gempt J; Ricklefs FL; Dührsen L
Neuro Oncol; 2023 May; 25(5):1006-1008. PubMed ID: 36860191
[No Abstract] [Full Text] [Related]
3. Association between thyroid function and regorafenib efficacy in patients with relapsed wild-type IDH glioblastoma: a large multicenter study.
Caccese M; Desideri I; Padovan M; Bruno F; Cerretti G; Fiorentino A; Denaro L; Chioffi F; Della Puppa A; Maccari M; Cavallin F; Coppola M; Pittaro A; Rudà R; Livi L; Lombardi G
J Neurooncol; 2023 Jun; 163(2):377-383. PubMed ID: 37264256
[TBL] [Abstract][Full Text] [Related]
4. Clinical and NGS predictors of response to regorafenib in recurrent glioblastoma.
Chiesa S; Mangraviti A; Martini M; Cenci T; Mazzarella C; Gaudino S; Bracci S; Martino A; Della Pepa GM; Offi M; Gessi M; Russo R; Martucci M; Beghella Bartoli F; Larocca LM; Lauretti L; Olivi A; Pallini R; Balducci M; D'Alessandris QG
Sci Rep; 2022 Sep; 12(1):16265. PubMed ID: 36171338
[TBL] [Abstract][Full Text] [Related]
5. O
Alassiri AH; Alkhaibary A; Al-Sarheed S; Alsufani F; Alharbi M; Alkhani A; Aloraidi A
Ann Saudi Med; 2019; 39(6):410-416. PubMed ID: 31804140
[TBL] [Abstract][Full Text] [Related]
6. Clinical significance of CDKN2A homozygous deletion in combination with methylated MGMT status for IDH-wildtype glioblastoma.
Funakoshi Y; Hata N; Takigawa K; Arita H; Kuga D; Hatae R; Sangatsuda Y; Fujioka Y; Sako A; Umehara T; Yoshitake T; Togao O; Hiwatashi A; Yoshimoto K; Iwaki T; Mizoguchi M
Cancer Med; 2021 May; 10(10):3177-3187. PubMed ID: 33838014
[TBL] [Abstract][Full Text] [Related]
7. Predictive value of MGMT promoter methylation on the survival of TMZ treated
Chai R; Li G; Liu Y; Zhang K; Zhao Z; Wu F; Chang Y; Pang B; Li J; Li Y; Jiang T; Wang Y
Cancer Biol Med; 2021 Feb; 18(1):272-282. PubMed ID: 33628600
[TBL] [Abstract][Full Text] [Related]
8. Partial resection offers an overall survival benefit over biopsy in MGMT-unmethylated IDH-wildtype glioblastoma patients.
Hallaert G; Pinson H; Vanhauwaert D; Van den Broecke C; Van Roost D; Boterberg T; Kalala JP
Surg Oncol; 2020 Dec; 35():515-519. PubMed ID: 33152608
[TBL] [Abstract][Full Text] [Related]
9. Updates in IDH-Wildtype Glioblastoma.
Melhem JM; Detsky J; Lim-Fat MJ; Perry JR
Neurotherapeutics; 2022 Oct; 19(6):1705-1723. PubMed ID: 35641844
[TBL] [Abstract][Full Text] [Related]
10. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas.
Christians A; Adel-Horowski A; Banan R; Lehmann U; Bartels S; Behling F; Barrantes-Freer A; Stadelmann C; Rohde V; Stockhammer F; Hartmann C
Acta Neuropathol Commun; 2019 Oct; 7(1):156. PubMed ID: 31623667
[TBL] [Abstract][Full Text] [Related]
11. Differentiating between glioblastomas with and without isocitrate dehydrogenase gene mutation by findings on conventional magnetic resonance images.
Shimizu T; Matsushima S; Fukasawa N; Akasaki Y; Mori R; Ojiri H
J Clin Neurosci; 2020 Jun; 76():140-144. PubMed ID: 32291242
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of IDH 1 mutation in patients with glioblastoma multiforme.
Khan I; Waqas M; Shamim MS
J Pak Med Assoc; 2017 May; 67(5):816-817. PubMed ID: 28507382
[TBL] [Abstract][Full Text] [Related]
13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
[TBL] [Abstract][Full Text] [Related]
14. IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma.
SongTao Q; Lei Y; Si G; YanQing D; HuiXia H; XueLin Z; LanXiao W; Fei Y
Cancer Sci; 2012 Feb; 103(2):269-73. PubMed ID: 22034964
[TBL] [Abstract][Full Text] [Related]
15. [IDH gene mutation in brain tumors].
Sonoda Y; Tominaga T
No Shinkei Geka; 2012 Apr; 40(4):297-306. PubMed ID: 22466228
[No Abstract] [Full Text] [Related]
16. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
[TBL] [Abstract][Full Text] [Related]
17. Molecular Correlates of Long Survival in IDH-Wildtype Glioblastoma Cohorts.
Galbraith K; Kumar A; Abdullah KG; Walker JM; Adams SH; Prior T; Dimentberg R; Henderson FC; Mirchia K; Sathe AA; Viapiano MS; Chin LS; Corona RJ; Hatanpaa KJ; Snuderl M; Xing C; Brem S; Richardson TE
J Neuropathol Exp Neurol; 2020 Aug; 79(8):843-854. PubMed ID: 32647886
[TBL] [Abstract][Full Text] [Related]
18. Comment on "The survival outcomes of molecular glioblastoma IDH-wildtype: a multicenter study".
Stoyanov GS
J Neurooncol; 2022 May; 157(3):573-574. PubMed ID: 35378641
[No Abstract] [Full Text] [Related]
19. The role of nonlinear dimension reduction of genome-wide DNA methylome in integrated diagnosis: A case study of glioblastoma, IDH-wildtype.
Satomi K; Saito K; Shimoyamada H; Onizuka H; Shibayama T; Hibiya T; Hayashi A; Nagahama K; Yamagishi Y; Sasaki N; Kobayashi K; Gomyo M; Nagane M; Shibahara J
Pathol Int; 2023 Oct; 73(10):523-526. PubMed ID: 37530489
[No Abstract] [Full Text] [Related]
20. Low MGMT digital expression is associated with a better outcome of IDH1 wildtype glioblastomas treated with temozolomide.
Gomes I; Moreno DA; Dos Reis MB; da Silva LS; Leal LF; Gonçalves GM; Pereira CA; Oliveira MA; de Medeiros Matsushita M; Reis RM
J Neurooncol; 2021 Jan; 151(2):135-144. PubMed ID: 33400009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
